Chromosomal Instability Associated with Improved Outcomes in Breast Cancer
the Cancer Therapy Advisor take:
There is an association between extreme chromosomal instability and improved outcome in estrogen receptor (ER)-negative breast cancers, a new study published online early in the journal Annals of Oncology has shown.
Previous studies have shown that extreme chromosomal instability is associated with improved clinical outcome in patients with ER-negative breast cancer, while it has been shown to be linked with drug resistance and poor outcomes in various other cancers.
For this study, researchers analyzed 1,173 tumors form the breast cancer TACT trial by performing dual centromeric fluorescence in situ hybridization for chromosomes 2 and 15.
Results showed that during a median follow-up of 91 months, extreme chromosomal instability was associated with improved clinical outcome in patients with ER-negative breast cancer (P trend = 0.03). In addition, researchers found that increasing chromosomal instability was associated with improved outcome in patients with ER-negative/HER2-negative breast cancers (P trend = 0.007).
Identifying patients with extreme chromosomal instability may help to predict prognosis and guide treatment decisions.
Association between extreme chromosomal instability and improved outcome in ER-negative breast cancers.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Questions Remain for First-line Treatment Selection and Sequencing in Advanced Melanoma
- Repeat T790M Testing Recommended for TKI-resistant Patients With NSCLC
- Ginkgo Biloba and Cancer
- Initial Therapy at Academic Centers Linked to Prolonged Overall Survival in NSCLC
- Affordable Care Act Linked to Lower Rates of Cancer Diagnosis Among Uninsured
- FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity
- PAK Inhibition Could Abrogate MAPK Inhibitor Resistance in BRAF-mutant Melanoma
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Atezolizumab Maintains Clinical Benefit After 2 Years in Advanced NSCLC